Drug Origin Transparency Act of 2023

The Drug Origin Transparency Act of 2023 requires drug manufacturers to report detailed supply chain information to the FDA, including the names and quantities of suppliers for each key drug ingredient. It directly affects drug manufacturers and distributors by mandating more frequent reporting (up to four times yearly) of ingredient sources and supply chain data. The bill also requires drug labels and certificates of analysis to include the original manufacturer's name, location, and unique facility identifier for active pharmaceutical ingredients. These changes aim to improve transparency in drug manufacturing origins without specifying exact implementation details, which will be set through future FDA regulations.